Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571675 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00571675 is a Phase 2 study that has completed, run by Ascenta Therapeutics. The registered enrollment target is 220 participants.
The verdict
NCT00571675, a Phase 2 study, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.
Interventions
- DRUG AT-101, prednisone and docetaxel
- DRUG placebo, prednisone and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571675
The ClinicalTrials.gov registry entry for NCT00571675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AT-101, prednisone and docetaxel is the first listed.
NCT00571675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571675 about?
NCT00571675 is a clinical study titled "A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)". This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who ...
What is the current status of trial NCT00571675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2007-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00571675?
The interventions under investigation include: AT-101, prednisone and docetaxel (DRUG), placebo, prednisone and docetaxel (DRUG).
Who is sponsoring clinical trial NCT00571675?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.